Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 19764029)


Complex contributions of Ets2 to craniofacial and thymus phenotypes of trisomic "Down syndrome" mice.

Hill CA, Sussan TE, Reeves RH, Richtsmeier JT.

Am J Med Genet A. 2009 Oct;149A(10):2158-65. doi: 10.1002/ajmg.a.33012.


Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice.

Sumarsono SH, Wilson TJ, Tymms MJ, Venter DJ, Corrick CM, Kola R, Lahoud MH, Papas TS, Seth A, Kola I.

Nature. 1996 Feb 8;379(6565):534-7.


Overlapping trisomies for human chromosome 21 orthologs produce similar effects on skull and brain morphology of Dp(16)1Yey and Ts65Dn mice.

Starbuck JM, Dutka T, Ratliff TS, Reeves RH, Richtsmeier JT.

Am J Med Genet A. 2014 Aug;164A(8):1981-90. doi: 10.1002/ajmg.a.36594. Epub 2014 May 1.


Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice.

Richtsmeier JT, Baxter LL, Reeves RH.

Dev Dyn. 2000 Feb;217(2):137-45.


Craniofacial phenotypes in segmentally trisomic mouse models for Down syndrome.

Richtsmeier JT, Zumwalt A, Carlson EJ, Epstein CJ, Reeves RH.

Am J Med Genet. 2002 Feb 1;107(4):317-24.


Ets transcription factors and targets in osteogenesis.

Raouf A, Seth A.

Oncogene. 2000 Dec 18;19(55):6455-63. Review.


Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome.

Billingsley CN, Allen JR, Baumann DD, Deitz SL, Blazek JD, Newbauer A, Darrah A, Long BC, Young B, Clement M, Doerge RW, Roper RJ.

Am J Med Genet A. 2013 Aug;161A(8):1866-74. doi: 10.1002/ajmg.a.36006. Epub 2013 Jul 10.


ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway.

Wolvetang EJ, Wilson TJ, Sanij E, Busciglio J, Hatzistavrou T, Seth A, Hertzog PJ, Kola I.

Hum Mol Genet. 2003 Feb 1;12(3):247-55.


A chromosome 21 critical region does not cause specific Down syndrome phenotypes.

Olson LE, Richtsmeier JT, Leszl J, Reeves RH.

Science. 2004 Oct 22;306(5696):687-90.


Increased male reproductive success in Ts65Dn "Down syndrome" mice.

Moore CS, Hawkins C, Franca A, Lawler A, Devenney B, Das I, Reeves RH.

Mamm Genome. 2010 Dec;21(11-12):543-9. doi: 10.1007/s00335-010-9300-8. Epub 2010 Nov 26.


Differential effects of trisomy on brain shape and volume in related aneuploid mouse models.

Aldridge K, Reeves RH, Olson LE, Richtsmeier JT.

Am J Med Genet A. 2007 May 15;143A(10):1060-70.


ETS family of genes in leukemia and Down syndrome.

Papas TS, Watson DK, Sacchi N, Fujiwara S, Seth AK, Fisher RJ, Bhat NK, Mavrothalassitis G, Koizumi S, Jorcyk CL, et al.

Am J Med Genet Suppl. 1990;7:251-61. Review.


Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome.

Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH.

Nature. 2008 Jan 3;451(7174):73-5. doi: 10.1038/nature06446.


Increased survival following tumorigenesis in Ts65Dn mice that model Down syndrome.

Yang A, Reeves RH.

Cancer Res. 2011 May 15;71(10):3573-81. doi: 10.1158/0008-5472.CAN-10-4489. Epub 2011 Apr 5.


The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome.

Belichenko NP, Belichenko PV, Kleschevnikov AM, Salehi A, Reeves RH, Mobley WC.

J Neurosci. 2009 May 6;29(18):5938-48. doi: 10.1523/JNEUROSCI.1547-09.2009.


The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome.

Wolvetang EW, Bradfield OM, Tymms M, Zavarsek S, Hatzistavrou T, Kola I, Hertzog PJ.

Biochim Biophys Acta. 2003 Jul 28;1628(2):105-10.


Trisomic and allelic differences influence phenotypic variability during development of Down syndrome mice.

Deitz SL, Roper RJ.

Genetics. 2011 Dec;189(4):1487-95. doi: 10.1534/genetics.111.131391. Epub 2011 Sep 16.


Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes.

Olson LE, Roper RJ, Baxter LL, Carlson EJ, Epstein CJ, Reeves RH.

Dev Dyn. 2004 Jul;230(3):581-9.


Reactive oxygen intermediates during programmed cell death induced in the thymus of the Ts(1716)65Dn mouse, a murine model for human Down's syndrome.

Paz-Miguel JE, Flores R, Sánchez-Velasco P, Ocejo-Vinyals G, Escribano de Diego J, López de Rego J, Leyva-Cobián F.

J Immunol. 1999 Nov 15;163(10):5399-410.


Potential contribution of SIM2 and ETS2 functional polymorphisms in Down syndrome associated malignancies.

Chatterjee A, Dutta S, Mukherjee S, Mukherjee N, Dutta A, Mukherjee A, Sinha S, Panda CK, Chaudhuri K, Roy AL, Mukhopadhyay K.

BMC Med Genet. 2013 Jan 23;14:12. doi: 10.1186/1471-2350-14-12.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk